Company: RCUS
Filing Date: 2025-04-22
Form Type: DEF 14A
Source: 0001724521-25-000052
Chunk: 61

Company: Arcus Biosciences, Inc.
Filing Date: 2025-04-22
Form: DEF 14A
Chunk 61
---
678,367 |     |      |    820,243 |
| Less, prior year fair value of prior year awards that failed to vest this year                                    |     |      |          — |     |      |          — |     |      |          — |     |      | -1,827,217 |     |      |          — |
| Plus adjustments for stock modification                                                                           |     |      |          — |     |      |          — |     |      |          — |     |      |     29,396 |     |      |          — |
| Total adjustments                                                                                                 |     |      | -1,097,011 |     |      | -1,240,351 |     |      | -6,585,692 |     |      |  1,152,169 |     |      |  5,091,852 |
| Compensation actually paid to Other NEOs                                                                          |     |      |  1,696,346 |     |      |  2,953,574 |     |      | -2,394,074 |     |      |  7,091,681 |     |      | 10,455,559 |

(5) TSR figures assume an initial investment in our common stock of $100 on December 31, 2019.The peer group referenced for purpose of the TSR comparison is the group of companies included in the S&P Biotechnology Index, which is the industry peer group used for purposes of Item 201(e) of Regulation S-K. The separate peer group used by the Compensation Committee for purposes of determining compensation paid to our executive officers is described on page 26.

(6) R eflects after-tax net income attributable to stockholders prepared in accordance with GAAP for each of the years shown.

Analysis of the Information Presented in the Pay versus Performance Table

As described above under “Compensation Discussion and Analysis,” our executive compensation program is built around a pay-for-performance framework. While we utilize various performance measures to align executive compensation with company performance, these measures are focused on the clinical development of our investigational products and, as such, are non-financial in nature. Moreover, we generally seek to incentivize long-term performance, and therefore do not specifically align the company’s performance measures with compensation that is actually paid (as computed in accordance with Item 402(v) of Regulation S-K) for a particular year. As a result, we do not have a financial performance measure as described in Item